Anti-inflammatory role of the cAMP effectors Epac and PKA: Implications in chronic obstructive pulmonary disease

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Oldenburger, Anouk ^a,d   Roscioni, Sara S ^a,d   Jansen, Esther ^a,d   Menzen, Mark H ^a,d   Halayko, Andrew J ^b   Timens, Wim ^c,d   Meurs, Herman ^a,d   Maarsingh, Harm ^a,d   Schmidt, Martina ^a,d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Groningen Research Institute for Asthma and COPD   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIGARETTE SMOKE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP EFFECTORS EPAC1; CYCLIC AMP EFFECTORS EPAC2; FENOTEROL; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; RAPGEF3 PROTEIN, HUMAN; RAPGEF4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR RELA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EXPOSURE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG PARENCHYMA; MALE; MOLECULAR MECHANICS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TARGETING; BRONCHUS; CELL NUCLEUS; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE SILENCING; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PROTEIN TRANSPORT; SECRETION; SIGNAL TRANSDUCTION; SMOKING; SMOOTH MUSCLE FIBER;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; BRONCHI; CELL NUCLEUS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FENOTEROL; GENE KNOCKDOWN TECHNIQUES; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; I-KAPPA B PROTEINS; INTERLEUKIN-8; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PROTEIN TRANSPORT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SIGNAL TRANSDUCTION; SMOKING; TRANSCRIPTION FACTOR RELA;

EID: 84857389753     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031574     Document Type: Article

References (48)

1. Hogg JC, Timens W, (2009) The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 4: 435-459.
2. Quint JK, Wedzicha JA, (2007) The neutrophil in chronic obstructive pulmonary disease. J Allergy Clin Immunol 119: 1065-1071.
3. Shapiro SD, Goldstein NM, Houghton AM, Kobayashi DK, Kelley D, et al. (2003) Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol 163: 2329-2335.
4. Stanescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, et al. (1996) Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 51: 267-271.
5. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA, (2006) Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173: 71-78.
6. Yamamoto C, Yoneda T, Yoshikawa M, Fu A, Tokuyama T, et al. (1997) Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 112: 505-510.
7. Keatings VM, Collins PD, Scott DM, Barnes PJ, (1996) Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153: 530-534.
8. Tanino M, Betsuyaku T, Takeyabu K, Tanino Y, Yamaguchi E, et al. (2002) Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema. Thorax 57: 405-411.
9. Mio T, Romberger DJ, Thompson AB, Robbins RA, Heires A, et al. (1997) Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am J Respir Crit Care Med 155: 1770-1776.
10. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, et al. (2005) Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 352: 1967-1976.
11. Mortaz E, Rad MV, Johnson M, Raats D, Nijkamp FP, et al. (2008) Salmeterol with fluticasone enhances the suppression of IL-8 release and increases the translocation of glucocorticoid receptor by human neutrophils stimulated with cigarette smoke. J Mol Med 86: 1045-1056.
12. Yang SR, Chida AS, Bauter MR, Shafiq N, Seweryniak K, et al. (2006) Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol 291: L46-L57.
13. Numanami H, Koyama S, Nelson DK, Hoyt JC, Freels JL, et al. (2003) Serine protease inhibitors modulate smoke-induced chemokine release from human lung fibroblasts. Am J Respir Cell Mol Biol 29: 613-619.
14. Oenema TA, Kolahian S, Nanninga JE, Rieks D, Hiemstra PS, et al. (2010) Pro-inflammatory mechanisms of muscarinic receptor stimulation in airway smooth muscle. Respir Res 11: 130.
15. Oltmanns U, Chung KF, Walters M, John M, Mitchell JA, (2005) Cigarette smoke induces IL-8, but inhibits eotaxin and RANTES release from airway smooth muscle. Respir Res 6: 74.
16. Karin M, Ben-Neriah Y, (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663.
17. Siebenlist U, Franzoso G, Brown K, (1994) Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10: 405-455.
18. Xie M, Liu XS, Xu YJ, Zhang ZX, Bai J, et al. (2008) Role of the extracellular signal-regulated kinase 1/2 signaling pathway in regulating the secretion of bronchial smooth muscle cells in a rat model of chronic asthma. Chin Med J (Engl) 121: 73-77.
19. Culpitt SV, Rogers DF, (2000) Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease. Expert Opin Pharmacother 1: 1007-1020.
20. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ, (1997) Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 155: 542-548.
21. Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, et al. (2006) Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173: 736-743.
22. Rabe KF, Wedzicha JA, (2011) Controversies in treatment of chronic obstructive pulmonary disease. Lancet 378: 1038-1047.
23. Giembycz MA, Newton R, (2006) Beyond the dogma: novel beta2-adrenoceptor signalling in the airways. Eur Respir J 27: 1286-1306.
24. Chiu JC, Hsu JY, Fu LS, Chu JJ, Chi CS, (2007) Comparison of the effects of two long-acting beta2-agonists on cytokine secretion by human airway epithelial cells. J Microbiol Immunol Infect 40: 388-394.
25. Hallsworth MP, Twort CH, Lee TH, Hirst SJ, (2001) beta(2)-adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells. Br J Pharmacol 132: 729-741.
26. Kaur M, Holden NS, Wilson SM, Sukkar MB, Chung KF, et al. (2008) Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A. Am J Physiol Lung Cell Mol Physiol 295: L505-L514.
27. Ammit AJ, Burgess JK, Hirst SJ, Hughes JM, Kaur M, et al. (2009) The effect of asthma therapeutics on signalling and transcriptional regulation of airway smooth muscle function. Pulm Pharmacol Ther 22: 446-454.
28. Shore SA, Moore PE, (2003) Regulation of beta-adrenergic responses in airway smooth muscle. Respir Physiol Neurobiol 137: 179-195.
29. Halayko AJ, Tran T, Gosens R, (2008) Phenotype and functional plasticity of airway smooth muscle: role of caveolae and caveolins. Proc Am Thorac Soc 5: 80-88.
30. Panettieri RA Jr, (2003) Airway smooth muscle: immunomodulatory cells that modulate airway remodeling? Respir Physiol Neurobiol 137: 277-293.
31. Roscioni SS, Kistemaker LE, Menzen MH, Elzinga CR, Gosens R, et al. (2009) PKA and Epac cooperate to augment bradykinin-induced interleukin-8 release from human airway smooth muscle cells. Respir Res 10: 88.
32. Jensen BO, Selheim F, Doskeland SO, Gear AR, Holmsen H, (2004) Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide. Blood 104: 2775-2782.
33. Pera T, Gosens R, Lesterhuis AH, Sami R, Toorn M, et al. (2010) Cigarette smoke and lipopolysaccharide induce a proliferative airway smooth muscle phenotype. Respir Res 11: 48.
34. Barnes PJ, (2008) The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 118: 3546-3556.
35. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG, (1995) Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 152: 1666-1672.
36. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, et al. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532-555.
37. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van SA, et al. (2009) Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 151: 517-527.
38. Oltmanns U, Walters M, Sukkar M, Xie S, Issa R, et al. (2008) Fluticasone, but not salmeterol, reduces cigarette smoke-induced production of interleukin-8 in human airway smooth muscle. Pulm Pharmacol Ther 21: 292-297.
39. Roscioni SS, Maarsingh H, Elzinga CR, Schuur LJ, Menzen MH, et al. (2010) Epac as a novel effector of airway smooth muscle relaxation. J Cell Mol Med In press.
40. Roscioni SS, Dekkers BG, Prins AG, Menzen MH, Meurs H, et al. (2011) cAMP inhibits modulation of airway smooth muscle phenotype via the exchange protein activated by cAMP (Epac) and protein kinase A. Br J Pharmacol 162: 193-209.
41. Foronjy R, Wallace A, D'Armiento J, (2008) The pharmokinetic limitations of antioxidant treatment for COPD. Pulm Pharmacol Ther 21: 370-379.
42. Yokoyama U, Patel HH, Lai NC, Aroonsakool N, Roth DM, et al. (2008) The cyclic AMP effector Epac integrates pro- and anti-fibrotic signals. Proc Natl Acad Sci U S A 105: 6386-6391.
43. Howarth PH, Beckett P, Dahl R, (2000) The effect of long-acting beta2-agonists on airway inflammation in asthmatic patients. Respir Med 94 (Suppl F): S22-S25.
44. Roberts JA, Bradding P, Britten KM, Walls AF, Wilson S, et al. (1999) The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 14: 275-282.
45. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, et al. (2007) Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 370: 2118-2125.
46. Boterman M, Smits SR, Meurs H, Zaagsma J, (2006) Protein kinase C potentiates homologous desensitization of the beta2-adrenoceptor in bovine tracheal smooth muscle. Eur J Pharmacol 529: 151-156.
47. Freyer AM, Billington CK, Penn RB, Hall IP, (2004) Extracellular matrix modulates beta2-adrenergic receptor signaling in human airway smooth muscle cells. Am J Respir Cell Mol Biol 31: 440-445.
48. Gosens R, Stelmack GL, Dueck G, McNeill KD, Yamasaki A, et al. (2006) Role of caveolin-1 in p42/p44 MAP kinase activation and proliferation of human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 291: L523-L534.